IONS Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of -46.06% compared to Ionis Pharmaceuticals's net margin of -14.12%. Ionis Pharmaceuticals's return on equity of -103.27% beat Alnylam Pharmaceuticals's return on equity of --.

Ionis Pharmaceuticals has a consensus price target of $59.50, signalling upside risk potential of 80.86%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $304.87 which suggests that it could grow by 26.11%. Given that Ionis Pharmaceuticals has higher upside potential than Alnylam Pharmaceuticals, analysts believe Ionis Pharmaceuticals is more attractive than Alnylam Pharmaceuticals.

Ionis Pharmaceuticals has a beta of 0.279, which suggesting that the stock is 72.122% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.76%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $226.6M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $593.2M. Ionis Pharmaceuticals's net income of -$104.3M is lower than Alnylam Pharmaceuticals's net income of -$83.8M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 6.98x versus 13.73x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Biogen has a net margin of -46.06% compared to Ionis Pharmaceuticals's net margin of 10.87%. Ionis Pharmaceuticals's return on equity of -103.27% beat Biogen's return on equity of 10.33%.

Ionis Pharmaceuticals has a consensus price target of $59.50, signalling upside risk potential of 80.86%. On the other hand Biogen has an analysts' consensus of $201.18 which suggests that it could grow by 43.72%. Given that Ionis Pharmaceuticals has higher upside potential than Biogen, analysts believe Ionis Pharmaceuticals is more attractive than Biogen.

Ionis Pharmaceuticals has a beta of 0.279, which suggesting that the stock is 72.122% less volatile than S&P 500. In comparison Biogen has a beta of 0.012, suggesting its less volatile than the S&P 500 by 98.773%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $226.6M, which are smaller than Biogen quarterly revenues of $2.5B. Ionis Pharmaceuticals's net income of -$104.3M is lower than Biogen's net income of $266.7M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Biogen's PE ratio is 12.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 6.98x versus 2.11x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Biomarin Pharmaceutical has a net margin of -46.06% compared to Ionis Pharmaceuticals's net margin of 16.72%. Ionis Pharmaceuticals's return on equity of -103.27% beat Biomarin Pharmaceutical's return on equity of 8.09%.

Ionis Pharmaceuticals has a consensus price target of $59.50, signalling upside risk potential of 80.86%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $95.68 which suggests that it could grow by 37.78%. Given that Ionis Pharmaceuticals has higher upside potential than Biomarin Pharmaceutical, analysts believe Ionis Pharmaceuticals is more attractive than Biomarin Pharmaceutical.

Ionis Pharmaceuticals has a beta of 0.279, which suggesting that the stock is 72.122% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.330, suggesting its less volatile than the S&P 500 by 67.009%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $226.6M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $747.3M. Ionis Pharmaceuticals's net income of -$104.3M is lower than Biomarin Pharmaceutical's net income of $124.9M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 31.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 6.98x versus 4.83x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -46.06% compared to Ionis Pharmaceuticals's net margin of 24.22%. Ionis Pharmaceuticals's return on equity of -103.27% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Ionis Pharmaceuticals has a consensus price target of $59.50, signalling upside risk potential of 80.86%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 35.62%. Given that Ionis Pharmaceuticals has higher upside potential than Regeneron Pharmaceuticals, analysts believe Ionis Pharmaceuticals is more attractive than Regeneron Pharmaceuticals.

Ionis Pharmaceuticals has a beta of 0.279, which suggesting that the stock is 72.122% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.13% to investors and pays a quarterly dividend of $0.88 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $226.6M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Ionis Pharmaceuticals's net income of -$104.3M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 6.98x versus 5.51x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.